JP2000506726A - 組換えａａｖベクターに基づく形質導入系およびその使用 - Google Patents
組換えａａｖベクターに基づく形質導入系およびその使用Info
- Publication number
- JP2000506726A JP2000506726A JP9531353A JP53135397A JP2000506726A JP 2000506726 A JP2000506726 A JP 2000506726A JP 9531353 A JP9531353 A JP 9531353A JP 53135397 A JP53135397 A JP 53135397A JP 2000506726 A JP2000506726 A JP 2000506726A
- Authority
- JP
- Japan
- Prior art keywords
- rep
- transduction system
- cells
- dna
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19608753.8 | 1996-03-06 | ||
| DE19608753A DE19608753C1 (de) | 1996-03-06 | 1996-03-06 | Transduktionssystem und seine Verwendung |
| PCT/DE1997/000447 WO1997032989A2 (de) | 1996-03-06 | 1997-03-06 | Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000506726A true JP2000506726A (ja) | 2000-06-06 |
| JP2000506726A5 JP2000506726A5 (enExample) | 2004-11-25 |
Family
ID=7787450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9531353A Ceased JP2000506726A (ja) | 1996-03-06 | 1997-03-06 | 組換えａａｖベクターに基づく形質導入系およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6207453B1 (enExample) |
| EP (1) | EP0891429A2 (enExample) |
| JP (1) | JP2000506726A (enExample) |
| DE (1) | DE19608753C1 (enExample) |
| WO (1) | WO1997032989A2 (enExample) |
Families Citing this family (202)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| DK1623017T3 (da) * | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
| US20070032570A1 (en) * | 2003-11-11 | 2007-02-08 | Canon Kabushiki Kaisha | Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same |
| EP1755400A2 (en) * | 2004-06-18 | 2007-02-28 | The University Of Montana | Aav mediated gene delivery to cochlear cells |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| ES2995052T3 (en) | 2014-04-23 | 2025-02-05 | Juno Therapeutics Inc | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| EP3209690B1 (en) | 2014-10-20 | 2021-05-05 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| WO2016073602A2 (en) | 2014-11-05 | 2016-05-12 | Juno Therapeutics, Inc. | Methods for transduction and cell processing |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| AU2016206457B2 (en) | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| MX2017015239A (es) | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| JP7245647B2 (ja) | 2015-07-15 | 2023-03-24 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法用の操作された細胞 |
| US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
| EP3365678A1 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods for culturing cells and kits and apparatus for same |
| IL258844B2 (en) | 2015-10-22 | 2024-03-01 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| MX2018005618A (es) | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| EP4212166A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
| AU2016363025B2 (en) | 2015-12-03 | 2021-04-08 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| EP3384294B1 (en) | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| US20190287013A1 (en) | 2016-03-16 | 2019-09-19 | Juno Therapeutics, Inc. | Methods for determining dosing of a therapeutic agent and related treatments |
| WO2017161212A1 (en) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| MA44486A (fr) | 2016-03-22 | 2019-01-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Procédés d'intervention précoce pour prévenir ou atténuer la toxicité |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| CA3022611A1 (en) | 2016-05-06 | 2017-11-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| CN109562127A (zh) | 2016-06-03 | 2019-04-02 | 纪念斯隆-凯特琳癌症中心 | 作为早期治疗选择的过继细胞疗法 |
| KR20240036704A (ko) | 2016-06-06 | 2024-03-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 이용한 b 세포 악성종양의 치료 방법 |
| US20190324030A1 (en) | 2016-06-27 | 2019-10-24 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| MA45455A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| MA45784A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
| MA46194A (fr) | 2016-09-12 | 2019-07-17 | Juno Therapeutics Inc | Ensembles de poches de bioréacteur de perfusion |
| EP3518943A4 (en) | 2016-09-28 | 2020-04-22 | Atossa Therapeutics, Inc. | METHOD FOR ADAPTIVE CELL THERAPY |
| MA46354A (fr) | 2016-10-03 | 2019-08-07 | Juno Therapeutics Inc | Molécules se liant spécifiquement au vph |
| WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| US20190298772A1 (en) | 2016-11-03 | 2019-10-03 | Juno Therapeutics, Inc. | Combination therapy of a t cell-based therapy and a btk inhibitor |
| US20190292246A1 (en) | 2016-11-03 | 2019-09-26 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia imhibitor |
| CN110494565A (zh) | 2016-12-02 | 2019-11-22 | 朱诺治疗学股份有限公司 | 工程化b细胞及相关组合物和方法 |
| WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| JP7227131B2 (ja) | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ－ｔ細胞の投薬を決定するための方法 |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| JP7359751B2 (ja) | 2017-03-14 | 2023-10-11 | ジュノー セラピューティクス インコーポレイテッド | 極低温保管のための方法 |
| JOP20180027A1 (ar) | 2017-03-28 | 2019-01-30 | Cell Design Labs Inc | بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها |
| US20230190796A1 (en) | 2017-04-07 | 2023-06-22 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| EP4647493A3 (en) | 2017-04-27 | 2026-01-14 | Juno Therapeutics, Inc. | Oligomeric particle reagents and methods of use thereof |
| CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| CN111201438A (zh) | 2017-06-02 | 2020-05-26 | 朱诺治疗学股份有限公司 | 与和细胞疗法相关的毒性有关的制品和方法 |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| AU2018287042A1 (en) | 2017-06-20 | 2020-02-06 | Centre National De La Recherche Scientifique - Cnrs - | Immune cells defective for Suv39h1 |
| WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
| ES3009018T3 (en) | 2017-07-29 | 2025-03-25 | Juno Therapeutics Inc | Reagents for expanding cells expressing recombinant receptors |
| WO2019032927A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF |
| KR20250096881A (ko) | 2017-08-09 | 2025-06-27 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포를 제조하기 위한 방법 및 조성물 |
| EP3676403A1 (en) | 2017-09-01 | 2020-07-08 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
| US20200292526A1 (en) | 2017-09-07 | 2020-09-17 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| CN111954679A (zh) | 2017-10-03 | 2020-11-17 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| SG11202003657VA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for producing a t cell composition |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| WO2019089884A2 (en) | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| CN111556893A (zh) | 2017-11-06 | 2020-08-18 | 爱迪塔斯医药股份有限公司 | 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分 |
| US12193994B2 (en) | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094835A1 (en) | 2017-11-10 | 2019-05-16 | Juno Therapeutics, Inc. | Closed-system cryogenic vessels |
| CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| US12570958B2 (en) | 2017-12-22 | 2026-03-10 | Cell Design Labs, Inc. | Single- and multi-chain chimeric antigen receptors |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| KR20200128014A (ko) | 2018-01-31 | 2020-11-11 | 셀진 코포레이션 | 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법 |
| US20210046159A1 (en) | 2018-03-09 | 2021-02-18 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| US12280119B2 (en) | 2018-03-23 | 2025-04-22 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| TWI840351B (zh) | 2018-04-05 | 2024-05-01 | 美商奇諾治療有限公司 | T細胞受體及表現其之工程化細胞 |
| KR20210029707A (ko) | 2018-04-05 | 2021-03-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물 |
| EP3775237A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| EP3787751A1 (en) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CA3102641A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| CA3108657A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| MX2021001519A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Metodos para valorar acidos nucleicos integrados. |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| EP3864025B1 (en) | 2018-10-12 | 2024-05-08 | Theradaptive, Inc. | Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof |
| US12522660B2 (en) | 2018-10-31 | 2026-01-13 | C3S2 Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| CA3116413A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
| CA3117720A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| ES2986007T3 (es) | 2018-11-30 | 2024-11-08 | Juno Therapeutics Inc | Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva |
| FI3886875T3 (fi) | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| AU2020265749A1 (en) | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| CA3139965A1 (en) | 2019-06-07 | 2020-12-10 | Ivie AIFUWA | Automated t cell culture |
| MA56206A (fr) | 2019-06-12 | 2022-04-20 | Juno Therapeutics Inc | Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie |
| US12109235B2 (en) | 2019-06-21 | 2024-10-08 | Kite Pharma, Inc. | TGF-beta receptors and methods of use |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| US12444491B2 (en) | 2019-08-30 | 2025-10-14 | Juno Therapeutics, Inc. | Machine learning methods for classifying cells |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| WO2021070956A1 (ja) | 2019-10-11 | 2021-04-15 | タカラバイオ株式会社 | ｓｉＲＮＡ発現ベクター |
| IL292319B2 (en) | 2019-10-30 | 2026-01-01 | C3S2 Gmbh | Cell selection and/or stimulation devices and methods of use |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| US20220401483A1 (en) | 2019-11-07 | 2022-12-22 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione |
| CN115335399A (zh) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
| CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
| IL293430A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| US20230071910A1 (en) | 2020-01-24 | 2023-03-09 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| MX2022009830A (es) | 2020-02-12 | 2022-10-28 | Juno Therapeutics Inc | Composiciones de celulas t que expresan receptores de antigenos quimericos dirigidos a bcma y metodos y usos de las mismas. |
| IL295384A (en) | 2020-02-12 | 2022-10-01 | Juno Therapeutics Inc | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
| BR112022020333A2 (pt) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b |
| BR112022020809A2 (pt) | 2020-04-15 | 2023-02-23 | Theradaptive Inc | Composições e métodos para entrega terapêutica direcionada ao osso |
| IL297688A (en) | 2020-04-28 | 2022-12-01 | Juno Therapeutics Inc | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| JP2023526278A (ja) | 2020-05-13 | 2023-06-21 | ジュノー セラピューティクス インコーポレイテッド | 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法 |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| CA3188656A1 (en) | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| EP4188395A1 (en) | 2020-07-30 | 2023-06-07 | Institut Curie | Immune cells defective for socs1 |
| US20230324408A1 (en) | 2020-08-05 | 2023-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
| EP4204447A1 (en) | 2020-08-28 | 2023-07-05 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| JP2023545731A (ja) | 2020-10-07 | 2023-10-31 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達 |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| TW202242121A (zh) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CA3210581A1 (en) | 2021-03-22 | 2022-09-29 | Neil HAIG | Methods of determining potency of a therapeutic cell composition |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| JP2024513054A (ja) | 2021-03-29 | 2024-03-21 | ジュノー セラピューティクス インコーポレイテッド | リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ |
| AU2022258832A1 (en) | 2021-04-16 | 2023-10-19 | Celgene Corporation | Combination therapies with bcma-directed t cell therapy |
| KR20240018454A (ko) | 2021-05-06 | 2024-02-13 | 주노 테라퓨틱스 게엠베하 | T 세포의 자극 및 형질도입 방법 |
| WO2022248602A1 (en) | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
| AU2022291365B2 (en) | 2021-06-08 | 2026-03-12 | Kite Pharma, Inc. | Gpc3 binding molecules |
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| KR20240112994A (ko) | 2021-11-03 | 2024-07-19 | 셀진 코포레이션 | 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체 |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| CA3247927A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| EP4473097A1 (en) | 2022-02-02 | 2024-12-11 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023164440A1 (en) | 2022-02-22 | 2023-08-31 | Juno Therapeutics, Inc. | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| EP4508073A1 (en) | 2022-04-14 | 2025-02-19 | Board of Regents of the University of Nebraska | Cell therapy for alzheimer's disease |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20250381272A1 (en) | 2022-06-22 | 2025-12-18 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| EP4544051A2 (en) | 2022-06-24 | 2025-04-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
| EP4547230A1 (en) | 2022-06-29 | 2025-05-07 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
| CA3261865A1 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| EP4573200A2 (en) | 2022-08-19 | 2025-06-25 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| AU2023329484A1 (en) | 2022-08-26 | 2025-02-20 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| CN120239746A (zh) | 2022-09-19 | 2025-07-01 | 图恩疗法股份有限公司 | 用于调节t细胞功能的组合物、系统和方法 |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| EP4611798A1 (en) | 2022-11-02 | 2025-09-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| JP2026501122A (ja) | 2022-12-09 | 2026-01-14 | ジュノー セラピューティクス インコーポレイテッド | ホログラフィックイメージングを使用して細胞表現型を予測するための機械学習方法 |
| CN120712102A (zh) | 2022-12-13 | 2025-09-26 | 朱诺治疗学股份有限公司 | 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途 |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| CN121127253A (zh) | 2023-02-28 | 2025-12-12 | 朱诺治疗学股份有限公司 | 治疗系统性自身免疫性疾病的细胞疗法 |
| CN121311765A (zh) | 2023-04-18 | 2026-01-09 | 朱诺治疗学股份有限公司 | 评估治疗性细胞组合物的效力的细胞毒性测定 |
| KR20260026101A (ko) | 2023-05-23 | 2026-02-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법 |
| WO2025029835A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for modulating il-2 gene expression |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059073A1 (en) | 2023-09-11 | 2025-03-20 | Tune Therapeutics, Inc. | Epigenetic editing methods and systems for differentiating stem cells |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025184421A1 (en) | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
| WO2026008700A1 (en) | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
| WO2026015647A1 (en) | 2024-07-09 | 2026-01-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5587308A (en) * | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| AU6427994A (en) * | 1993-03-19 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Process for preparing cancer vaccines |
| US5693531A (en) * | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
| FR2716893B1 (fr) * | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
| US6342390B1 (en) * | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
| DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
-
1996
- 1996-03-06 DE DE19608753A patent/DE19608753C1/de not_active Expired - Fee Related
-
1997
- 1997-03-06 JP JP9531353A patent/JP2000506726A/ja not_active Ceased
- 1997-03-06 WO PCT/DE1997/000447 patent/WO1997032989A2/de not_active Ceased
- 1997-03-06 US US09/142,289 patent/US6207453B1/en not_active Expired - Fee Related
- 1997-03-06 EP EP97918010A patent/EP0891429A2/de not_active Withdrawn
-
2001
- 2001-01-31 US US09/773,302 patent/US6440742B1/en not_active Expired - Fee Related
-
2002
- 2002-08-12 US US10/218,280 patent/US20020192826A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6207453B1 (en) | 2001-03-27 |
| EP0891429A2 (de) | 1999-01-20 |
| WO1997032989A3 (de) | 1998-01-15 |
| WO1997032989A2 (de) | 1997-09-12 |
| US6440742B1 (en) | 2002-08-27 |
| US20020192826A1 (en) | 2002-12-19 |
| US20020028514A1 (en) | 2002-03-07 |
| DE19608753C1 (de) | 1997-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000506726A (ja) | 組換えａａｖベクターに基づく形質導入系およびその使用 | |
| US11117933B2 (en) | Selective recovery | |
| JP4860886B2 (ja) | 二本鎖パルボウイルスベクター | |
| US6365403B1 (en) | High-efficiency AAV helper functions | |
| JP2001506133A (ja) | 組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株 | |
| JP2005110694A (ja) | 高力価組換えａａｖベクターの生成 | |
| CN115151647A (zh) | Dna扩增方法 | |
| JP2022505816A (ja) | 小型化ジストロフィンおよびそれらの使用 | |
| KR20230019162A (ko) | Smn1 단백질을 코딩하는 코돈-최적화된 핵산 | |
| JP2001520047A (ja) | 組換えａａｖベクターと共に使用するための転写活性化された逆方向末端反復（ｉｔｒ） | |
| CN101405033A (zh) | 增强感染性细小病毒载体在昆虫细胞中的生产 | |
| Xiao et al. | Adeno-associated virus (AAV) vectors for gene transfer | |
| JP2001502549A (ja) | ヘルパーウイルス配列を含有するａａｖ ｄｎａ | |
| Kaplitt et al. | Gene therapy of the central nervous system: from bench to bedside | |
| JP2000512501A (ja) | Ａａｖベクターの生産系 | |
| WO2025057943A1 (ja) | 内耳に感染性を有するａａｖ変異体 | |
| AU2024342045A1 (en) | Aav variant capable of infecting inner ear | |
| HK40016209A (en) | Selective recovery | |
| JP2003511038A (ja) | 単純化したａａｖ産生のための材料および方法 | |
| Bottles | AAV VECTORS PRODUCTION AND SPECIFIC APPLICATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061010 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070302 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070403 |